qfx

And so it is with Nvidia, a company whose very name now seems to embody the relentless march of technological progress. The current price, a mere $178 per share at this writing, belies the expectations held by those who study its fortunes. An average price target of $265 suggests a potential ascent of nearly fifty percent within a year – a considerable gain, yet one that seems almost… understated, given the forces at play. That Nvidia, the largest company measured by market capitalization, should present such an opportunity is a paradox worthy of note. It is not merely a question of financial gain, but of observing the unfolding of a new era.

They import cheap cosmetics. Brilliant. Groundbreaking. Seriously, that’s the strategy? It works, apparently. Revenue keeps going up. It’s like people just need more eyeliner. And they expand into new categories. More stuff. More… consumption. It’s a never-ending cycle. And they’re making money doing it. Fine. But it doesn’t make it a good investment, just a… successful one. There’s a difference. A big difference.

Pershing Square, his vessel, had no holdings in this particular dominion at the quarter’s start. Now, it constitutes over eleven percent of the fund’s holdings. A deliberate weighting, not a casual toss of dice. It suggests a conviction, a belief in the underlying growth, a sense that the current valuation does not fully reflect the potential bloom. But is this a bloom accessible to all, or merely a private garden for the well-funded?

The company’s fortunes, like those of a young lady entering society, have experienced a degree of fluctuation over the past year, particularly in the vicinity of its quarterly pronouncements. However, a recent report of strong fiscal results for the third quarter of 2026 has provided a distinctly upward turn, the stock currently enjoying a rise of approximately fifteen percent over the preceding twelve months, though it remains somewhat diminished from its earlier peak.

Numerous pharmaceutical houses, both established and nascent, have turned their gaze toward this burgeoning market, lured by the prospect of alleviating a widespread affliction and, of course, by the accumulation of considerable wealth. Few, however, possess the resources and resolve to mount a genuine challenge to Eli Lilly’s authority. Let us consider, then, those who might yet disturb the prevailing order.

VGT, in its infinite wisdom, attempts to encompass the entirety of the US tech sector – over 300 companies, a number that’s frankly terrifying when you consider how many meetings must have been required to decide which ones to include. SOXX, meanwhile, restricts itself to a mere 30 semiconductor manufacturers. This isn’t necessarily a sign of discipline, mind you. It could just be that someone in the marketing department really, really likes silicon. The question, of course, is whether you want a diversified portfolio or a highly concentrated bet on the continued existence of integrated circuits. (Which, admittedly, is a fairly safe bet. For now.)